Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vasovist-enhanced MR angiography.

Mathias Goyen1, Kohkan Shamsi, Stefan O Schoenberg

  • 1University Medical Center, Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. goyen@uke.uni-hamburg.de

European Radiology
|June 28, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adoption, orchestration, and deployment of artificial intelligence within the National Health Service-facilitators and barriers: an expert roundtable discussion.

BJR artificial intelligence·2026
Same author

When radiology stops being a specialty.

European journal of radiology·2026
Same author

pRECIST: Guidelines for Response Criteria for Use in Trials Testing Therapeutics in Pancreatic Cancer.

Pancreas·2026
Same author

Comparing quantitative image parameters between animal and clinical CT-scanners: a translational phantom study analysis.

Frontiers in medicine·2024
Same author

Virtual Non-Contrast versus True Native in Photon-Counting CT: Stability of Density of Upper Abdominal Organs and Vessels.

Diagnostics (Basel, Switzerland)·2024
Same author

Streamlining Acute Abdominal Aortic Dissection Management-An AI-based CT Imaging Workflow.

Journal of imaging informatics in medicine·2024
Same journal

ESR Essentials: pelvic floor imaging-practice recommendations by the European Society of Urogenital Radiology.

European radiology·2026
Same journal

STIR or T2-Dixon? A false dilemma in musculoskeletal MRI.

European radiology·2026
Same journal

ESR Essentials: uterine cancers-practice recommendations by the European Society of Urogenital Radiology.

European radiology·2026
Same journal

Adjunctive quantification for more reproducible amyloid PET interpretation.

European radiology·2026
Same journal

APEX-NET: automated pancreatic evaluation network using early non-contrast CT.

European radiology·2026
Same journal

Temporal bone remodeling after venous stenting for pulsatile tinnitus: isolated dehiscence versus diverticulum.

European radiology·2026
See all related articles

Vasovist (MS-325), a novel intravascular contrast agent, offers extended enhancement for magnetic resonance angiography. Clinical trials confirm its safety and superior accuracy in diagnosing vascular stenosis and aneurysms compared to non-contrast methods.

Area of Science:

  • Radiology
  • Cardiovascular Imaging
  • Pharmacology

Background:

  • Vasovist (MS-325) is the first intravascular contrast agent approved in the EU for magnetic resonance angiography (MRA).
  • It exhibits unique albumin-binding properties, prolonging intravascular enhancement beyond conventional extracellular agents.
  • Extensive pre-approval testing assessed its safety and efficacy across diverse clinical scenarios.

Purpose of the Study:

  • To evaluate the safety and efficacy of Vasovist for magnetic resonance angiography.
  • To compare Vasovist-enhanced MRA with non-contrast MRA and conventional angiography.
  • To assess Vasovist's performance in various vascular beds and potential drug interactions.

Main Methods:

  • Blinded, placebo-controlled, dose-ranging clinical trials.

Related Experiment Videos

  • Efficacy assessments in peripheral (AIOD, pedal) and renal vascular beds.
  • Comparative studies against X-ray angiography (XRA) and non-contrast MRA.
  • Evaluation of drug interactions with warfarin.

    • Main Results:

    • Vasovist-enhanced MRA demonstrated safety and good tolerability in patients with vascular disease.
    • The agent proved effective for detecting vascular stenosis and aneurysms.
    • Significantly higher sensitivity and specificity were observed compared to non-contrast MRA for diagnosing stenoses.
    • Overall characterization of vascular disease was comparable to conventional angiography, without catheterization.

    Conclusions:

    • Vasovist is a safe and effective contrast agent for MRA in patients with vascular disease.
    • Vasovist-enhanced MRA offers improved diagnostic accuracy for vascular stenoses over non-contrast MRA.
    • It provides a valuable, non-invasive alternative to conventional angiography for vascular disease assessment.